Gusperimus

Summary

Gusperimus (CHEMBL406117) is a phase-3 clinical-stage small molecule (ATC L04AA19); indicated across 2 conditions including immune system disorder and granulomatosis with polyangiitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L04AA19
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 387.5 Da · C17H37N7O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL406117
Name	Gusperimus
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	55362
ATC	L04AA19
Molecular formula	C17H37N7O3
Molecular weight	387.5
InChIKey	IDINUJSAMVOPCM-UHFFFAOYSA-N

SMILES: C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O

IUPAC name: N-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide

Also known as: Gusperimus, GUSPERIMUS, gusperimus

Parent form; salt/anhydrous children: CHEMBL1996913, CHEMBL2356648

Patent coverage: 3,729 distinct patent families (15,442 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,206 (79%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
immune system disorder	3	MONDO:0005046	EFO:0000540
granulomatosis with polyangiitis	3	MONDO:0012105	EFO:0005297

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01446211	PHASE3	TERMINATED	Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis
NCT00530075	PHASE2	COMPLETED	Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).